Home > Protocol Summaries: Compounds > abacavir Protocol Summaries: abacavir GSKStudy ID Phase Title Status 100327 Phase 4 See Detailed Description Completed 111950 n\a Fractures over time stratified by HIV infection and Antiretroviral Therapy (ART) exposure Completed 112872 n\a HIV treatment and CVD events - Ingenix. Retrospective Database Analysis of Patients with Human Immunodeficiency Virus (HIV) Treatment and Cardiovascular Disease (CVD) Events Completed 112885 n\a Antiretroviral Pregnancy Registry (APR)-Risk of birth defects associated with exposure to GSK HIV drugs during pregnancy Recruiting 114382 An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ZIAGEN® administered in Korean patients according to the prescribing information Recruiting ABC107442 Phase 4 A retrospective case-control study to estimate the sensitivity and specificity of a pharmacogenetic marker (HLA-B*5701) in subjects with and without hypersensitivity to abacavir. Completed CAL102120 phase 1 An open-label, two-period, crossover, pharmacokinetic study of abacavir and its intracellular anabolite carbovir triphosphate following once-daily and twice-daily administration of abacavir in HIV-infected subjects. Completed CAL30001 phase 3 See Detailed Description Completed CNA106030 Phase 4 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Completed CNA108223 Phase 4 A retrospective, multi-centre observational study to evaluate disease management and adverse events in adult subjects with HIV-1 infection who were withdrawn from CNA106030 due to a positive HLA-B*5701 test result Completed CNA109479 phase 4 Prospective epidemiological study of the prevalence of HLA-B*5701 in HIV-1 infected UK patients Completed CNA109586 phase 4 Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects Completed CNA110329 Phase 4 Prospective epidemiological study of the prevalence of HLA-B*5701 in HIV-1 infected patients Completed EPZ104057 Phase 4 A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects Completed
